 |
|
|
| |
Safety and Efficacy of DTG by Age, Race and Gender: Subgroup Analysis of 96 Week Results From Treatment-Naive Patients in Phase III Trials (SPRING-2 [ING113086], SINGLE [ING114467] and FLAMINGO [ING114915])
|
| |
| |
Reported by Jules Levin
8th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 19-22, 2015; Vancouver, Canada
Koteff,1 R Cuffe,2 C Granier,3 A Zolopa,1 A Murungi,2 B Wynne,4 M Aboud,2 K Smith1 1ViiV Healthcare, Research Triangle Park, NC, USA; 2ViiV Healthcare, Middlesex, United Kingdom; 3GlaxoSmithKline, London, United Kingdom; 4GlaxoSmithKline, Research Triangle Park, NC, USA
|
| |
|
|
|
|
|
